Fig. 3From: A multi-parametric prognostic model based on clinical features and serological markers predicts overall survival in non-small cell lung cancer patients with chronic hepatitis B viral infectionDecision curve analysis for each model in training cohort (a) and validation cohort (b). The thick grey line is the net benefit for a strategy of treating all men; the thick black line is the net benefit of treating no men. The y-axis indicate the net benefit, which is calculated by summing the benefits (true positive results) and subtracting the harms (false positive results), weighting the latter by a factor related to the relative harm of an undetected cancer compared with the harm of unnecessary treatmentBack to article page